We have shown that HOIPIN-1 serves as an additional anti-inflammatory therapeutic tool to treat psoriasis, since it suppresses the expression of IL-23/IL-17, which is crucial for the Th1, Th17, and ILC3 cell-mediated pathogenesis of psoriasis50, and has no apparent side effects, unlike clobetasol, a steroid drug. Here, IL17A is linked to psoriasis.